Abstract:Influenza virus causes influenza, an infectious disease. The symptoms can range from mild to severe. Severe influenza infections have historically led to 250,000 to 500,000 deaths per year. Influenza viruses can be broadly classified into four types as A, B, C, and D. They are structurally similar, and place high demands on drugs. The heterotrimeric polymerase complex of the influenza virus represents a promising target for the design and improvement of novel lead compounds. Inhibition of its assembly could be proven to have an antiviral efficacy for both in vitro and in vivo activity. However, in vivo, potent lead compounds tackling this target have not been identified yet. In this study, we have used the information about two previously discovered molecules (referred to as ANA 1 and PAC-3), which revealed significant in vitro effects, and we have proposed new compounds using a computational protocol. Structural, chemical similarity calculations against the ZINC database were carried out using the Generic Match Algorithm (GMA). Putative inhibitor binding sites of the influenza virus polymerase were investigated based on the blind docking approach employing AutoDock Vina and Lead Finder. Furthermore, ligand-based virtual screenings were executed, calculating shape similarity using a Weighted Gaussian Algorithm (WEGA) and pharmacophoric properties by LigandScout. A handful of molecules were finally selected as promising inhibitors. The binding efficiency and the toxicity properties of the identified lead compound DB07972 (MolPort-002-025-261) were compared against the available drug of choice Baloxavir marboxil. The molecular dynamics simulations along with the MMPBSA calculations have shown that the novel lead compound DB07972 is capable of exhibiting better interaction and compactness. More interestingly, the novel lead compound was found to be less toxic than the control drug. The molecule was further evaluated using in vitro approaches. From the experimental analysis, the chosen compound, DB07972, showed maximal inhibition around 75% with 20 μM and was non-toxic to 100% healthy cells at the same concentration.

Identification of influenza polymerase inhibitors targeting C-terminal domain of PA through surface plasmon resonance screening

Identification of influenza polymerase inhibitors targeting polymerase PB2 cap-binding domain through virtual screening

Identification of Novel Influenza Polymerase PB2 Inhibitors Using a Cascade Docking Virtual Screening Approach

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds

Prediction and characterization of influenza virus polymerase inhibitors through blind docking and ligand based virtual screening

Identification of influenza A nucleoprotein as an antiviral target

Virtual Screening and Molecular Dynamics Simulation Study of Influenza Polymerase PB2 Inhibitors

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

A Parallel Phenotypic Versus Target-Based Screening Strategy For Rna-Dependent Rna Polymerase Inhibitors Of The Influenza A Virus

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

Structural and free energy landscape analysis for the discovery of antiviral compounds targeting the cap-binding domain of influenza polymerase PB2

Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins

Identification of Influenza PAN Endonuclease Inhibitors via 3D-QSAR Modeling and Docking-Based Virtual Screening

Discovery of a potent inhibitor targeting the cap-binding domain of the PB2 subunit of influenza RNA-dependent RNA polymerase

Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization

Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA–PB1 Subunits Interaction

Understanding the stability and dynamics of influenza a H5N1 polymerase PB2 CAP-Binding domain in complex with natural compounds for antiviral drug discovery

Optimization of 4-Aminopiperidines As Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir

Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors